Tuesday, March 17, 2026

Inside North Korea’s English-Speaking Tours: Harry Potter, Beer Jokes, and Fluent English?

The Pyongyang International Marathon highlights North Korean tour guides' impressive English skills and evolving tourism dynamics.

HOLD MY BEER, America! Australia Does The Job RIGHT, Slapping Sanctions On Kim’s Cybergang

Australia imposes sanctions on North Korean groups funding weapons development, targeting cybercrime and illicit revenue streams.

SK Chemicals’ Joins Tablet Surpasses 700 Billion KRW in Sales… What’s Behind the Osteoarthritis Drug’s Success?

SK Chemicals' Joins Tablets, a natural osteoarthritis treatment, surpasses 700 billion KRW in sales, marking a significant milestone in Korea.

Tag: diabetes

North KoreaKoreaKimMilitarySouth KoreaAIrelationsmarketInternational

New Diabetes Treatment: Chong Kun Dang’s Dubiempol Sustained Release Tablet Approved for Type 2 Diabetes in Korea

Chong Kun Dang's type 2 diabetes treatment, Dubiempol, gains approval, offering a new option for patients with uncontrolled blood sugar.

Novo Nordisk Slashes GLP-1 Drug Prices by Up to 50%: What This Means for Obesity Treatments in 2027

Novo Nordisk will cut prices of GLP-1 treatments in the U.S. by up to 50% from January 2027, amid rising competition and market pressures.

HM15275 Clinical Trials: What You Need to Know About This Groundbreaking Obesity Treatment

Hanmi Pharmaceutical's HM15275 enters Phase 2 trial, aiming to revolutionize obesity treatment and diabetes management by 2030.

Rising Use of GLP-1 Drugs May Be Linked to Rare Pancreatitis Cases, Study Finds

Reports of acute pancreatitis linked to GLP-1 diabetes drugs surge in the UK, prompting investigations and conflicting academic findings.

One in Three Diabetes Patients at Risk for Kidney Disease, Study Finds

Diabetes can lead to kidney disease, affecting one in three patients. Early detection and nephrology care are crucial for better outcomes.

Novo Nordisk and Lilly Block Generics, Tighten Grip on $125B GLP-1 Market

Novo Nordisk and Eli Lilly secure court victories against generics, maintaining dominance in the GLP-1 treatment market amid rising demand.

Eli Lilly’s Oral GLP-1 Shows 7.9% Weight Loss in Type 2 Diabetes Trial

Eli Lilly's orforglipron shows promise in Phase 3 trials for diabetes and obesity, offering an oral alternative to injectables.

Diabetes Risk for 40% of Adults: How a New Nutrition Guide is Helping

Korea's Food and Drug Safety Ministry launched a guide for prediabetes management, improving dietary habits for better health outcomes.

Study Reveals Semaglutide Reduces Cravings and Helps Control Weight and Blood Sugar

A study shows oral semaglutide aids weight loss and reduces cravings for sugary foods in type 2 diabetes patients.

Study Reveals: Taking Statins for 3 Years Can Slash Dementia Risk by 63%!

A study reveals statins can reduce dementia risk by 63%, especially in diabetic patients, highlighting their protective benefits.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.